HKEX Anchor Fund vs Buying Hong Kong Stocks Directly: What Is the Real Difference?

"Getting exposure to Hong Kong equities" can mean two very different things. You can open a brokerage account and buy shares yourself — including applying for IPOs through the public tranche — or you can subscribe to a fund that participates in IPO anchor placements on your behalf. They touch the same market, but they are not interchangeable products. They differ in what you can access, what you actually own, how much control you keep, and how you can exit. This article compares them so you can tell which question you are really asking. It is educational and not investment advice.

They Solve Different Problems

Buying stocks directly is an access-and-control product: you decide what to buy and when to sell, and you own the shares outright. An IPO anchor fund is an allocation-and-structure product: you are paying a manager to obtain institutional-channel allocations you could not get yourself, inside a structure you do not control. Neither is strictly better. The right one depends on whether your constraint is what to buy or getting into deals you cannot otherwise reach.

Side by Side

Reading the Table Honestly

A few rows deserve more than a cell:

Allocation is the fund's actual claim. The reason to consider an anchor fund is not that it removes risk — it is that the public tranche of a popular Hong Kong IPO fills individual applicants at minimal size, if at all. The fund's proposition is institutional-scale allocation through the offline channel. If that access is not something you value, most of the fund's rationale disappears and direct investing is simpler.

Control and liquidity move together, and against you. Buying shares directly, you can exit any trading day and correct your own mistakes. In the fund, you hand both the selection and the exit timing to the manager, and your capital is committed for the closed term. That is the price of the allocation access — less control, less liquidity.

The risks are different in kind, not just size. Direct investing concentrates risk in your own judgment. The fund replaces that with manager risk, structure risk, and the currency seam between USDT and the underlying fiat market. Swapping one set of risks for another is a real decision, not an upgrade.

The Same IPO Through Both Routes

It helps to trace a single Hong Kong listing through each path, without inventing any numbers.

Through direct investing, you decide the listing interests you, apply through the public tranche, and receive whatever allocation the oversubscription leaves you — often a fraction of what you asked for on a popular deal, or nothing. If you are allocated, you hold the shares directly and choose when to sell: on the first day, weeks later, or never. Every outcome, good or bad, traces back to your own decisions about which deal and what timing.

Through the anchor fund, you never see that individual decision. The manager decides whether the listing meets its screening standards, the pooled fund receives an offline allocation at institutional scale, and the manager sells in stages on its own schedule. You are not allocated to that specific stock — you hold a fund interest whose value reflects the blended result of every deal the fund entered, minus fees, converted back through the currency layer. One strong listing does not flow straight to you; it is diluted and averaged across the portfolio and the term.

The same event, in other words, reaches you as a discrete, controllable position in one route and as one input to a pooled, delegated result in the other. That difference — not the headline appeal of any single IPO — is what you are actually choosing between.

What Each Route Cannot Do

Being explicit about the limits prevents the most common mistakes.

Direct investing cannot manufacture allocation. No matter how well you pick, the public tranche of an oversubscribed deal will not give an individual meaningful size. If your interest is specifically in the early-listing window on popular names, direct application is structurally the wrong tool — you can be right about the deal and still receive almost none of it.

The fund cannot give you selectivity or an early exit. You cannot tell the fund to skip a deal you dislike or to hold a winner longer. You accept the manager's whole process, and your capital stays committed for the closed term regardless of what any single position does. The fund also cannot remove the currency seam: even a portfolio that performs well in HKD can reach you differently after conversion.

Neither limit is a flaw. They are the defining trade of each structure — control and selectivity on one side, access and scale on the other — and paying attention to which limit you can live with is more useful than comparing hoped-for returns.

The Cost and Diligence Trade

The two routes also move the work around rather than removing it. Direct investing spreads a recurring research burden across every company you consider, and its costs are transaction-level — commissions and fees each time you act. The fund concentrates the burden into a single, heavier diligence exercise on the manager, the structure, and the terms, done once before subscribing, and moves the cost into fund-level fees that apply whether or not a given cycle performs. Cheaper headline transactions do not make direct investing "lower cost" in every case, and a single diligence pass does not make the fund "less work" if you skip it — an unread structure is where most fund-product risk hides.

Which Question Are You Asking?

If your question is "which Hong Kong companies do I want to own, and when," you are describing direct investing — a fund does not answer it. If your question is "how could I access IPO allocations that the public channel will not give me, and I am willing to accept a closed term and manager control to get there," you are describing what an anchor fund is for. Answering that honestly tells you which product to study, before you look at any expected outcome.

For the fund's full structure, see inside the HKEX Anchor Investment Flagship Fund; for how to assess one, see how to evaluate an IPO anchor fund. The fund's product page, formal documents, and risk disclosures are on Bifu — review them and weigh the product against your own risk tolerance and eligibility.

FAQ

Do you need a Hong Kong brokerage account to buy Hong Kong stocks directly?

Yes. Buying Hong Kong-listed shares directly requires a brokerage account with access to the Hong Kong exchange, whether through a local broker or an international broker offering HK market access, and that same account is how you would apply for the public tranche of an IPO. An anchor fund does not require this step, since the fund subscribes to placements on your behalf.

Is an HKEX anchor fund the same as an ETF that tracks Hong Kong stocks?

No. An ETF holds a basket of shares that are already listed and trades on an exchange throughout the day, while an HKEX anchor fund is a closed-end structure that participates in IPO anchor placements before shares list, with capital locked up for a fixed term. The two give different exposure: an ETF tracks the broader market, while an anchor fund's result depends on specific new listings and the manager's allocation and exit decisions.

Can you invest in both direct Hong Kong stocks and an anchor fund?

Yes, the two are not mutually exclusive. Buying shares directly and subscribing to an anchor fund solve different problems — one gives you control over specific stocks, the other gives you access to institutional IPO allocations — so some investors use both depending on what they are trying to achieve. Each still carries its own risks and diligence requirements, and one does not offset the other.

Are HKEX IPO anchor funds only for Hong Kong listings, or do they cover other exchanges too?

This comparison covers anchor funds specifically tied to HKEX listings. Anchor investing as a strategy is not exclusive to Hong Kong, but the manager, structure, and access described here apply to HKEX IPOs, so check a fund's own documents to confirm which exchange it covers before assuming a product works the same way elsewhere.